Alain Bitton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1059756/publications.pdf

Version: 2024-02-01

186265 114465 4,257 76 28 63 h-index citations g-index papers 76 76 76 5115 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nature Genetics, 2001, 29, 223-228.	21.4	730
2	Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet, The, 2015, 386, 1825-1834.	13.7	354
3	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. Gastroenterology, 2015, 148, 1035-1058.e3.	1.3	323
4	Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology. Gastroenterology, 2014, 146, 835-848.e6.	1.3	277
5	Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology, 2019, 156, 1345-1353.e4.	1.3	273
6	Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases. American Journal of Gastroenterology, 2017, 112, 1120-1134.	0.4	241
7	Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 1427-1434.e2.	4.4	187
8	Psychosocial Determinants of Relapse in Ulcerative Colitis: A Longitudinal Study. American Journal of Gastroenterology, 2003, 98, 2203-2208.	0.4	183
9	Sex-Based Differences in Incidence of Inflammatory Bowel Diseasesâ€"Pooled Analysis of Population-Based Studies From Western Countries. Gastroenterology, 2018, 155, 1079-1089.e3.	1.3	155
10	Oral Corticosteroids and the Risk of Serious Infections in Patients With Elderly-Onset Inflammatory Bowel Diseases. American Journal of Gastroenterology, 2014, 109, 1795-1802.	0.4	107
11	Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ: British Medical Journal, 2018, 360, k872.	2.3	89
12	Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort Study. American Journal of Gastroenterology, 2017, 112, 1412-1422.	0.4	88
13	Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis. Journal of Crohn's and Colitis, 2014, 8, 1632-1641.	1.3	83
14	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Inflammatory Bowel Diseases, 2019, 25, 1-13.	1.9	73
15	Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. Inflammatory Bowel Diseases, 2019, 25, 124-133.	1.9	60
16	Epidemiology of Inflammatory Bowel Disease in Québec. Inflammatory Bowel Diseases, 2014, 20, 1770-1776.	1.9	58
17	Increased incidence of inflammatory bowel disease in Québec residents with airway diseases. European Respiratory Journal, 2015, 45, 962-968.	6.7	50
18	Risk Factors Associated with <i>Clostridium difficile </i> Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Journal of Crohn's and Colitis, 2019, 13, 27-38.	1.3	49

#	Article	IF	CITATIONS
19	Mortality Trends in Crohnʽs Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, 416-423.	1.9	48
20	Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. Clinical Epidemiology, 2018, Volume 10, 1613-1626.	3.0	48
21	Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut, 2017, 66, 1390-1397.	12.1	45
22	Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis. Journal of Crohn's and Colitis, 2020, 14, 46-52.	1.3	40
23	Inflammatory bowel disease and airway diseases. World Journal of Gastroenterology, 2016, 22, 7735.	3.3	39
24	Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review. Clinical Gastroenterology and Hepatology, 2019, 17, 1265-1275.e8.	4.4	36
25	Anti-Microbial Antibody Response is Associated With Future Onset of Crohn's Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. Gastroenterology, 2021, 161, 1540-1551.	1.3	35
26	Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab. Inflammatory Bowel Diseases, 2018, 24, 1531-1538.	1.9	34
27	Patients' perception of their involvement in shared treatment decision making: Key factors in the treatment of inflammatory bowel disease. Patient Education and Counseling, 2018, 101, 331-339.	2.2	32
28	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1680-1713.	4.4	32
29	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2019, 2, e1-e34.	0.3	32
30	Inflammatory bowel disease and risk of mortality in COPD. European Respiratory Journal, 2016, 47, 1357-1364.	6.7	29
31	Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease. Saudi Journal of Gastroenterology, 2019, 25, 159.	1.1	27
32	Selection of Quality Indicators in IBD: Integrating Physician and Patient Perspectives. Inflammatory Bowel Diseases, 2019, 25, 403-409.	1.9	25
33	Herpes Zoster Incidence in Inflammatory Bowel Disease Patients: A Population-Based Study. Inflammatory Bowel Diseases, 2019, 25, 914-918.	1.9	25
34	Occult Dysplasia in a Localized Giant Pseudopolyp in Crohn's Colitis: A Case Report. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 477-478.	1.7	23
35	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. Journal of Rheumatology, 2019, 46, 751-754.	2.0	22
36	Inflammatory bowel disease patient perceptions of diagnostic and monitoring tests and procedures. BMC Gastroenterology, 2019, 19, 30.	2.0	21

#	Article	IF	CITATIONS
37	Inflammatory Bowel Disease Increases the Risk of Venous Thromboembolism in Children: A Population-Based Matched Cohort Study. Journal of Crohn's and Colitis, 2021, 15, 2031-2040.	1.3	20
38	Risk of Malignant Cancers in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2019, 13, 1302-1310.	1.3	19
39	Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activityâ€"A Retrospective Study. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-7.	1.9	17
40	Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-NaÃ⁻ve Crohn's Disease. Digestive Diseases and Sciences, 2018, 63, 1302-1310.	2.3	16
41	High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival. Digestive Diseases and Sciences, 2019, 64, 518-523.	2.3	16
42	Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-9.	1.9	16
43	No Change in Surgical and Hospitalization Trends Despite Higher Exposure to Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease in the Québec Provincial Database From 1996 to 2015. Inflammatory Bowel Diseases, 2021, 27, 655-661.	1.9	14
44	High Adherence to Surveillance Guidelines in Inflammatory Bowel Disease Patients Results in Low Colorectal Cancer and Dysplasia Rates, While Rates of Dysplasia are Low Before the Suggested Onset of Surveillance. Journal of Crohn's and Colitis, 2019, 13, 1343-1350.	1.3	13
45	Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic. Digestive and Liver Disease, 2019, 51, 340-345.	0.9	12
46	Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center. Digestive Diseases and Sciences, 2020, 65, 2046-2053.	2.3	11
47	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Journal of the Canadian Association of Gastroenterology, 2018, 1, 141-154.	0.3	10
48	Serum Analyte Profiles Associated With Crohn's Disease and Disease Location. Inflammatory Bowel Diseases, 2022, 28, 9-20.	1.9	10
49	Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies. Digestive and Liver Disease, 2018, 50, 37-41.	0.9	9
50	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. Journal of the Canadian Association of Gastroenterology, 2021, 4, S46-S53.	0.3	9
51	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations. Journal of the Canadian Association of Gastroenterology, 2021, 4, S54-S60.	0.3	9
52	Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes. World Journal of Gastroenterology, 2020, 26, 759-769.	3.3	8
53	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. Journal of the Canadian Association of Gastroenterology, 2021, 4, S61-S67.	0.3	7
54	Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response. Journal of the Canadian Association of Gastroenterology, 2022, 5, 208-213.	0.3	6

#	Article	IF	CITATIONS
55	Preventing Postoperative Recurrence in Crohn $\hat{E}^{1}\!/4$ s Disease With 6-Mercaptopurine and Azathioprine: Approaching the Cutting Edge. Inflammatory Bowel Diseases, 2005, $11,513-514$.	1.9	5
56	A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 2695-2702.	2.3	5
57	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S1-S9.	0.3	5
58	Decline in IBD Incidence in Québec. Inflammatory Bowel Diseases, 2014, 20, 1782-1783.	1.9	4
59	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S40-S45.	0.3	4
60	Patient Perspectives of IBD Care and Services: An Integral Part of a Pan-Canadian Quality Improvement Initiative. Journal of the Canadian Association of Gastroenterology, 2021, 4, 229-233.	0.3	4
61	Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study. Digestive Diseases and Sciences, 2021, , 1.	2.3	4
62	The Burden of Anemia Remains Significant over Time in Patients with Inflammatory Bowel Diseases at a Tertiary Referral Center. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 555-559.	0.9	4
63	Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996–2015. Journal of Clinical Medicine, 2022, 11, 686.	2.4	4
64	Do You See What I See? An Assessment of Endoscopic Lesions Recognition and Description by Gastroenterology Trainees and Staff Physicians. Journal of the Canadian Association of Gastroenterology, 2020, 3, 216-221.	0.3	3
65	Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy. Digestive Diseases and Sciences, 2021, 66, 1650-1657.	2.3	3
66	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S27-S33.	0.3	3
67	Anti-TNF Therapy and the Risk of Herpes Zoster Among Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 176-182.	1.9	3
68	Development of a Global Rating Scale for Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology, 2020, 3, 4-16.	0.3	2
69	Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Disease in Canada: A Knowledge Translation Strategy. Journal of the Canadian Association of Gastroenterology, 2021, 4, S10-S19.	0.3	2
70	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. Journal of the Canadian Association of Gastroenterology, 2021, 4, S34-S39.	0.3	2
71	Novel Negative Pressure Box for Aerosol Protection During Upper Endoscopy: A Brief Report on Safety and Barrier Performance. American Journal of Gastroenterology, 2020, 115, 1936-1936.	0.4	2
72	IBD-associated G protein-coupled receptor 65 variant compromises signalling and impairs key functions involved in inflammation. Cellular Signalling, 2022, 93, 110294.	3.6	2

Alain Bitton

#	Article	IF	CITATION
73	Fucosyltransferase 2 Mutations Are Associated With a Favorable Clinical Course in Crohn's Disease. Journal of Clinical Gastroenterology, 2022, 56, e166-e170.	2.2	1
74	ANTI-TUMOR NECROSIS FACTOR α: CROHN'S DISEASE GUIDED MISSILE. Inflammatory Bowel Diseases, 1998, 173-174.	4 1.9	0
75	Reply to Letter on: â€~Risk Factors Associated With <i>Clostridium difficile</i> Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis'. Journal of Crohn's and Colitis, 2019, 13, 536-537.	1.3	0
76	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S20-S26.	0.3	0